Catalyst Pharmaceuticals Inc Total Assets
Catalyst Pharmaceuticals Inc total assets. Based on the latest financial reports, Catalyst Pharmaceuticals Inc (CPRX) holds total assets worth $1.15 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CPRX market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Catalyst Pharmaceuticals Inc (2002–2025)
Total assets of Catalyst Pharmaceuticals Inc from 2002 to 2025. This chart illustrates how Catalyst Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See Catalyst Pharmaceuticals Inc stock quote for real-time trading data and today's change.
Catalyst Pharmaceuticals Inc - Asset Composition Analysis
Catalyst Pharmaceuticals Inc Total Assets Breakdown (December 2025)
Catalyst Pharmaceuticals Inc total assets breakdown as of December 2025. Catalyst Pharmaceuticals Inc's total assets of $1.15 Billion consist of 80.8% current assets and 19.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 64.1% |
| Accounts Receivable | $128.27 Million | 11.6% |
| Inventory | $37.17 Million | 3.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $131.67 Million | 11.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Catalyst Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Catalyst Pharmaceuticals Inc (CPRX) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Catalyst Pharmaceuticals Inc's current assets represent 80.8% of total assets in 2025, a decrease from 96.0% in 2002.
- Cash Position: Cash and equivalents constituted 64.1% of total assets in 2025, down from 96.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 11.9% of total assets.
Catalyst Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Catalyst Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Catalyst Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.10 | 6.14 | 10.93 |
| Quick Ratio | 6.84 | 5.96 | 10.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $807.99 Million | $574.07 Million | $160.17 Million |
Catalyst Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Catalyst Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.81 |
| Latest Market Cap to Assets Ratio | 3.48 |
| Asset Growth Rate (YoY) | 30.0% |
| Total Assets | $1.11 Billion |
| Market Capitalization | $3.85 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Catalyst Pharmaceuticals Inc's assets at a significant premium (3.48x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Catalyst Pharmaceuticals Inc's assets grew by 30.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Catalyst Pharmaceuticals Inc (2002–2025)
The table below shows the annual total assets of Catalyst Pharmaceuticals Inc from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.11 Billion | +30.00% |
| 2024-12-31 | $851.41 Million | +81.11% |
| 2023-12-31 | $470.11 Million | +25.15% |
| 2022-12-31 | $375.63 Million | +57.97% |
| 2021-12-31 | $237.79 Million | +23.62% |
| 2020-12-31 | $192.35 Million | +71.17% |
| 2019-12-31 | $112.38 Million | +85.90% |
| 2018-12-31 | $60.45 Million | -29.21% |
| 2017-12-31 | $85.39 Million | +104.73% |
| 2016-12-31 | $41.71 Million | -30.61% |
| 2015-12-31 | $60.10 Million | +36.88% |
| 2014-12-31 | $43.91 Million | +73.07% |
| 2013-12-31 | $25.37 Million | +51.11% |
| 2012-12-31 | $16.79 Million | +168.66% |
| 2011-12-31 | $6.25 Million | +7.16% |
| 2010-12-31 | $5.83 Million | -26.80% |
| 2009-12-31 | $7.97 Million | -33.80% |
| 2008-12-31 | $12.03 Million | -27.86% |
| 2007-12-31 | $16.68 Million | -19.11% |
| 2006-12-31 | $20.62 Million | +2511.88% |
| 2005-12-31 | $789.45K | +325.86% |
| 2004-12-31 | $185.38K | +66.12% |
| 2002-12-31 | $111.59K | -- |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more